First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.
Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity
Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.
Two cohort studies presented at CROI 2017 showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.
There is a significant "statin treatment gap" for people living with HIV, with only 47% of people eligible for statins receiving them in 2013, according to a recent study.
On behalf of TheBodyPRO.com, Terri Wilder, M.S.W., spoke with Elske Hoornenborg, M.D., who presented a case study of HIV transmission despite good adherence to pre-exposure prophylaxis (PrEP) and no drug resistance, at CROI 2017.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
"Overall, we saw improvements for the whole population, suggesting that the efforts to test [and] diagnose HIV infection sooner, start [antiretroviral] treatment earlier and help patients be retained in care and adherent to their treatment are workin...
Three large clinical trials -- involving thousands of men in Africa -- have shown that male circumcision reduces risk of HIV acquisition.
Due to the impact of the Affordable Care Act (ACA), in just two years the proportion of people living with HIV in care covered by Medicaid increased from 36% to 42% and the proportion that were uninsured fell from 18% to 14%.
If you're a provider, you want to offer patients the latest, evidence-based ways to reduce their risk for HIV -- including women who may have increased risk because of the microbes in their genital tracts.